4.6 Article

Examining different measures of multimorbidity, using a large prospective cross-sectional study in Australian general practice

期刊

BMJ OPEN
卷 4, 期 7, 页码 -

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2013-004694

关键词

-

资金

  1. Australian Government Department of Health and Ageing
  2. Australian Government Department of Veterans' Affairs
  3. Australian Institute of Health and Welfare
  4. National Prescribing Service
  5. AstraZeneca Pty Ltd (Australia)
  6. Janssen-Cilag Pty Ltd
  7. Merck
  8. Sharpe and Dohme (Australia) Pty Ltd
  9. Pfizer Australia Pty Ltd
  10. Abbott Australasia Pty Ltd
  11. Sanofi-Aventis Australia Pty Ltd
  12. Novartis Pharmaceuticals Australia Pty Ltd

向作者/读者索取更多资源

Objectives: Prevalence estimates of multimorbidity vary widely due to inconsistent definitions and measurement methods. This study examines the independent effects on prevalence estimates of how 'disease entity' is defined-as a single chronic condition or chapters/domains in the International Classification of Primary Care (V.2; ICPC-2), International Classification of Disease (10th revision; ICD-10) or the Cumulative Illness Rating Scale (CIRS), the number of disease entities required for multimorbidity, and the number of chronic conditions studied. Design: National prospective cross-sectional study. Setting: Australian general practice. Participants: 8707 random consenting deidentified patient encounters with 290 randomly selected general practitioners. Main outcome measures: Prevalence estimates of multimorbidity using different definitions. Results: Data classified to ICPC-2 chapters, ICD-10 chapters or CIRS domains produce similar multimorbidity prevalence estimates. When multimorbidity was defined as two or more (2+) disease entities: counting individual chronic conditions and groups of chronic conditions produced similar estimates; the 12 most prevalent chronic conditions identified about 80% of those identified using all chronic conditions. When multimorbidity was defined as 3+ disease entities: counting individual chronic conditions produced significantly higher estimates than counting groups of chronic conditions; the 12 most prevalent chronic conditions identified only two-thirds of patients identified using all chronic conditions. Conclusions: Multimorbidity defined as 2+ disease entities can be measured using different definitions of disease entity with as few as 12 prevalent chronic conditions, but lacks specificity to be useful, especially in older people. Multimorbidity, defined as 3+, requires more measurement conformity and inclusion of all chronic conditions, but provides greater specificity than the 2+ definition. The proposed concept of complex multimorbidity, the co-occurrence of three or more chronic conditions affecting three or more different body systems within one person without defining an index chronic condition, may be useful in identifying high-need individuals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据